Novo Nordisk, Eli Lilly fall after Trump comments on weight loss drug pricing
Investing.com - Morgan Stanley has downgraded Straumann Holding AG (SWX:STMN) stock rating from Equalweight to Underweight, while significantly reducing its price target to CHF75.00 from CHF120.00.
The downgrade comes amid persistent weakness in Straumann’s North American business, which has been decelerating over the past eight quarters with little evidence of an imminent recovery, according to Morgan Stanley’s analysis.
The investment bank cited macroeconomic uncertainty and weaker consumer credit appetite for financing dental implant treatments in the high interest rate environment as key factors behind Straumann’s challenges.
US consumer credit data remains in negative territory as of July 2025, contradicting consensus expectations for growth acceleration in the third and fourth quarters, Morgan Stanley noted in its research.
Morgan Stanley’s 2026 forecast for Straumann’s North American organic growth stands at 5%, below the consensus estimate of 7%, with the bank’s recent dental implant survey pointing to below-average near-term demand trends.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.